| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNF43 |
| Uniprot No | Q68DV7-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-197aa |
| 氨基酸序列 | MSGGHQLQLA ALWPWLLMAT LQAGFGRTGL VLAAAVESER SAEQKAIIRV IPLKMDPTGK LNLTLEGVFA GVAEITPAEG KLMQSHPLYL CNASDDDNLE PGFISIVKLE SPRRAPRPCL SLASKARMAG ERGASAVLFD ITEDRAAAEQ LQQPLGLTWP VVLIWGNDAE KLMEFVYKNQ KAHVRIELKE PPAWPDY |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNF43重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Tumor suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors*
**作者**: Koo B.K. et al.
**摘要**: 该研究揭示了RNF43作为Wnt信号通路的负调控因子，通过其E3泛素连接酶活性泛素化Frizzled受体，促进其内吞和溶酶体降解，从而抑制Wnt信号传导。研究中使用重组RNF43蛋白验证了其对Frizzled的泛素化功能。
2. **文献名称**: *ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner*
**作者**: Hao H.X. et al.
**摘要**: 本文发现RNF43与ZNRF3协同作用，通过泛素化Wnt受体调控其膜稳定性。重组RNF43蛋白的体外实验表明，其活性可被R-spondin蛋白抑制，揭示了肠道干细胞稳态的分子机制。
3. **文献名称**: *Structural basis of RNF43-mediated Wnt receptor phospho-ubiquitination*
**作者**: Jiang X. et al.
**摘要**: 该研究通过解析RNF43重组蛋白的晶体结构，阐明了其胞外结构域与Wnt配体的相互作用模式，以及胞内结构域催化受体泛素化的机制，为靶向RNF43的癌症治疗提供了结构基础。
---
以上文献均涉及RNF43重组蛋白在Wnt信号调控、泛素化功能及结构解析中的关键作用，涵盖功能验证、相互作用机制及结构生物学研究。
RNF43 (Ring Finger Protein 43) is a transmembrane E3 ubiquitin ligase that plays a critical role in regulating cellular signaling pathways, particularly the Wnt/β-catenin pathway. It is characterized by an N-terminal signal peptide, a protease-associated (PA) domain, a transmembrane domain, and a C-terminal RING finger domain responsible for its ubiquitin ligase activity. RNF43 targets Wnt receptors, Frizzled (FZD), and LRP5/6 co-receptors for ubiquitination and subsequent degradation via the proteasome, acting as a negative regulator of Wnt signaling—a pathway essential for embryonic development, tissue homeostasis, and stem cell maintenance.
Dysregulation of RNF43 is implicated in various cancers. Loss-of-function mutations or epigenetic silencing of RNF43 are frequently observed in colorectal, ovarian, and pancreatic cancers, leading to hyperactivated Wnt signaling and uncontrolled cell proliferation. Conversely, in certain contexts, RNF43 overexpression may promote tumorigenesis through non-canonical mechanisms, highlighting its context-dependent roles. These dual effects make RNF43 a compelling therapeutic target.
Recombinant RNF43 protein, typically produced in mammalian or insect expression systems, retains enzymatic activity and structural integrity for functional studies. It is widely used in biochemical assays to investigate ubiquitination mechanisms, screen for modulators of Wnt signaling, or develop targeted therapies. For instance, RNF43 recombinant protein aids in studying interactions with ZNRF3 (a homolog) or testing inhibitors that stabilize FZD receptors. Additionally, it serves as an antigen for antibody development in diagnostic tools or antibody-based therapies. Research on RNF43 recombinant protein continues to advance our understanding of Wnt-related pathologies and precision medicine strategies for cancers with aberrant Wnt activation. Its therapeutic potential is further underscored by ongoing efforts to design small molecules or biologics that mimic or inhibit RNF43 activity to restore Wnt pathway homeostasis.
×
